Skip to main content

Revelation Biosciences, Inc.

REVB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001810560

No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.

Other share classesREVBW

Q3 2022 vs. Q2 2022

How the institutions holding Revelation Biosciences, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of REVB: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders1214+2
Shares3.22M2.25M−968.6K (−30.1%)
Value$3.57M$588.6K−$2.98M (−83.5%)

New holders (7)

Institutions that held Revelation Biosciences, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to REVB in Q3 2022
InstitutionSharesValue% of portfolio
State Street Corp108,828$28.0K0.00%
Millennium Management LLC48,690$13.0K0.00%
Citadel Advisors LLC22,547$6.00K0.00%
Two Sigma Securities, LLC21,748$6.00K0.00%
Two Sigma Investments, LP18,081$5.00K0.00%
FMR LLC10,000$3.00K0.00%
Renaissance Technologies LLC11,942$3.00K0.00%

Sold out (5)

Institutions that held Revelation Biosciences, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of REVB in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Monashee Investment Management LLC817,562$907.0K
Citigroup Inc258,649$287.0K
Bridgeway Capital Management, LLC121,263$135.0K
HRT Financial LP10,922$12.0K
UBS Group AG5,062$6.00K